S Cannavo1, M Ragonese1, S Puglisi1, P D Romeo1, M L Torre1, A Alibrandi1, C Scaroni1, G Occhi1, F Ceccato1, D Regazzo1, E De Menis1, P Sartorato1, G Arnaldi1, L Trementino1, F Trimarchi1, F Ferrau1. 1. Department of Clinical and Experimental Medicine-Endocrinology Unit (S.C., M.R., S.P., P.D.R., M.L.T., F.T., F.F.), and Department of Economics (A.A.), University of Messina, 98100 Messina, Italy; Endocrinology Unit, Department of Medicine (C.S., G.O., F.C., D.R.), DIMED, University of Padua, 35128 Padua, Italy; Department of Internal Medicine (E.D., P.S.), General Hospital, 31044 Montebelluna, Italy; and Department of Endocrinology and Metabolic Diseases (G.A., L.T.), Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, 60126 Ancona, Italy.
Abstract
CONTEXT: An increased prevalence of acromegaly was found some years ago in a highly polluted area in North-Eastern Sicily, where high concentration of nonmethane hydrocarbons, volatile organic compounds, and cadmium was found. Aryl hydrocarbon receptor (AHR) pathway has a key role in detoxification of these compounds and in tumorigenesis. OBJECTIVE: We correlated the occurrence of AHR and/or AHR-interacting protein (AIP) gene variants with acromegaly severity according to pollution exposition. DESIGN, SETTING, and PATIENTS: This was an observational, perspective study conducted over 7 years in four Italian referral centers for pituitary diseases in which 210 patients with acromegaly were enrolled between 2008 and 2015. INTERVENTION: Genetic screening of patients for AHR and AIP variants. MAIN OUTCOME MEASURES: Clinical, biochemical, and radiological data of patients with and without AIP and/or AHR gene variants, living in polluted (high-risk for health, [HR]) or nonpolluted (NP) areas of five Italian regions were evaluated and compared. RESULTS: Among the 23 patients from HR areas, nine showed AHR or AIP variants. Mean IGF-I levels and pituitary tumor diameter were significantly higher in these nine patients (HR/VAR+) than in the other 14 (HR/VAR−) and in the 187 from NP areas (44 NP/VAR+). Somatostatin analogs significantly decreased mean GH and IGF-I levels in patients from NP areas and in HR/VAR− (GH P < .05; IGF-I times the upper limit of normal P < .01) but not in HR/VAR+ group. CONCLUSIONS: Genetic variants potentially inducing functional abnormalities of the aryl hydrocarbon receptor (AHR) pathway are associated with a more severe acromegaly, increased pituitary tumor size, and somatostatin analog resistance in patients living in HR areas.
CONTEXT: An increased prevalence of acromegaly was found some years ago in a highly polluted area in North-Eastern Sicily, where high concentration of nonmethane hydrocarbons, volatile organic compounds, and cadmium was found. Aryl hydrocarbon receptor (AHR) pathway has a key role in detoxification of these compounds and in tumorigenesis. OBJECTIVE: We correlated the occurrence of AHR and/or AHR-interacting protein (AIP) gene variants with acromegaly severity according to pollution exposition. DESIGN, SETTING, and PATIENTS: This was an observational, perspective study conducted over 7 years in four Italian referral centers for pituitary diseases in which 210 patients with acromegaly were enrolled between 2008 and 2015. INTERVENTION: Genetic screening of patients for AHR and AIP variants. MAIN OUTCOME MEASURES: Clinical, biochemical, and radiological data of patients with and without AIP and/or AHR gene variants, living in polluted (high-risk for health, [HR]) or nonpolluted (NP) areas of five Italian regions were evaluated and compared. RESULTS: Among the 23 patients from HR areas, nine showed AHR or AIP variants. Mean IGF-I levels and pituitary tumor diameter were significantly higher in these nine patients (HR/VAR+) than in the other 14 (HR/VAR−) and in the 187 from NP areas (44 NP/VAR+). Somatostatin analogs significantly decreased mean GH and IGF-I levels in patients from NP areas and in HR/VAR− (GH P < .05; IGF-I times the upper limit of normal P < .01) but not in HR/VAR+ group. CONCLUSIONS: Genetic variants potentially inducing functional abnormalities of the aryl hydrocarbon receptor (AHR) pathway are associated with a more severe acromegaly, increased pituitary tumor size, and somatostatin analog resistance in patients living in HR areas.
Authors: Maria Florencia Torti; Federico Giovannoni; Francisco Javier Quintana; Cybele Carina García Journal: Front Immunol Date: 2021-03-05 Impact factor: 7.561
Authors: I Schofield; D C Brodbelt; S J M Niessen; D B Church; R F Geddes; D G O'Neill Journal: J Small Anim Pract Date: 2021-12-08 Impact factor: 1.669
Authors: Pedro Marques; Sayka Barry; Amy Ronaldson; Arla Ogilvie; Helen L Storr; Peter J Goadsby; Michael Powell; Mary N Dang; Harvinder S Chahal; Jane Evanson; Ajith V Kumar; Joan Grieve; Márta Korbonits Journal: Int J Endocrinol Date: 2018-04-04 Impact factor: 2.803
Authors: Pedro de Pablos-Velasco; Eva María Venegas; Cristina Álvarez Escolá; Carmen Fajardo; Paz de Miguel; Natividad González; Ignacio Bernabéu; Nuria Valdés; Miguel Paja; Juan José Díez; Betina Biagetti Journal: Pituitary Date: 2020-04 Impact factor: 4.107